September, 22 2016 - Globally, over 22,000 people die of cancer each day. When cancer is detected at the early stages, survival rates are generally still high. Finding cancer early with an accurate, convenient and affordable technology, and attacking it early, can vastly reduce cancer deaths, and substantially lower cancer-related healthcare expenditures.
NEW YORK - (BUSINESS WIRE) - iCareDx, Inc., a biotechnology company focused on blood-based early detection of cancer, today announced that it has changed its name to Acuamark Diagnostics, Inc. In conjunction with its corporate name change, the Company’s website will be available at www.acuamarkdx.com.
Dr. Bernard Peperstraete, CEO of Acuamark Diagnostics, Inc. (formerly iCareDx, Inc.) stated, "Our team is excited to re-brand the Company as Acuamark Diagnostics. The name “Acuamark” incorporates several elements that play to the essence of our corporate mission, and well embodies the progress we have made towards developing an accurate diagnostic screening technology to detect low-abundance tumor markers from liquids at the earliest stages of cancer.”
Dr. Francis Barany, PhD, Professor of Microbiology and Immunology at the Weill Cornell Medicine, and lead inventor of Acuamark Diagnostics’ molecular detection technologies, adds: “In addition, the name Acuamark Diagnostics is a reflection that each cancer leaves a unique watermark in our bodies, and as with a watermark, it is barely visible, requiring one to see it in a different light.”
About Acuamark Diagnostics Inc.
Acuamark Diagnostics is a biotechnology company focused on developing screening tests technologies for blood-based early detection of cancer. Acuamark Diagnostics' technology allows for highly accurate screening of blood to detect cancer markers at the early cancer stages, before the cancer becomes untreatable. Backed by a highly experienced team, it is Acuamark Diagnostics’ mission to contribute to the global battle against cancer by detecting and attacking cancer through high-precision, early detection.